About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

Annual Report and Form 20-F 2023 Haleon at a glance | We are a global leader in the growing consumer healthcare market: | | | | | | | --- | --- | --- | --- | --- | --- | | £190bn | 5 9 £11.3bn | | | | | | Market1 | Global categories1 Power Brands Revenue | | | | | | Our purpose: | To deliver better everyday health with humanity | | | | | | Our strategy: | Our strategy is designed to leverage our portfolio and capabilities | | | | | | | and has four key pillars: | | | | | | | 1 2 3 4 | | | | | | | Increase C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File ...

Financial Data and Key Metrics - Gross margin increased by 70 basis points in Q4, driven by easing inflationary pressures and pricing strategies [24] - The company ended the year with a strong cash position of £1 billion, allowing it to pay back a $700 million bond due in March and distribute dividends [11] - Operating profit grew nearly three points ahead of the rate of sales growth in 2023, with a 60 basis points margin improvement [45][69] Business Line Performance - Respiratory health division saw strong growth in Q4, with a 7.5% increase in the back half of the year, driven by geographic diversity and product portfolio strength [64][65] - Oral health segment performed well, with strong growth in Sensodyne and other brands, supported by innovation and pricing strategies [104][131] - VMS (Vitamins, Minerals, and Supplements) showed improvement, particularly with Centrum and Caltrate, driven by clinical studies and marketing support [60][61] Market Performance - In China, the OTC business saw significant demand due to COVID-related restrictions being lifted, with strong performance in Q1 and Q2 expected [22][34] - North America experienced a challenging environment in respiratory health, with flat performance in the back half of the year, while other regions like Central Eastern Europe, Japan, and Turkey saw higher growth [64][65] - India saw high single-digit sales growth, with Sensodyne leading with double-digit growth, despite some disruptions from the transition from Hindustan Unilever [88][89] Strategic Direction and Industry Competition - The company is focusing on innovation, with 67 new product launches in 2023, including Sensodyne Clinical White and other oral health products [15][121] - A&P (Advertising and Promotion) spend is being actively managed, with a focus on investing in growth areas and optimizing returns, particularly in oral health and VMS [2][16][48] - The company is targeting a 50-50 split between volume and price growth in the long term, with 2024 being a stepping stone towards this goal [50][137] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the 4% to 6% sales growth guidance for 2024, with organic profit expected to grow ahead of sales growth [21][28] - The company is managing inflationary pressures and expects gross margin to continue growing ahead of sales growth, supported by pricing and productivity programs [24][25] - The respiratory health market is expected to normalize, with fluctuations of plus or minus 0.5% to 1% in extreme seasons [65] Other Important Information - The company is actively managing its portfolio, with divestments and potential bolt-on acquisitions to strengthen its business [75][146] - A £500 million share buyback program is planned for 2024, with flexibility to execute it through open market purchases or placings with GSK and Pfizer [86][145] - The company is targeting a medium-term leverage ratio of around 2.5x, supported by strong cash generation and debt reduction efforts [129][101] Q&A Session Summary Question: Net benefit from savings in 2025 and A&P spend drivers - The company did not provide specific net benefit figures for 2025 but mentioned that productivity programs will provide a tailwind for 2024 [3] - A&P spend in 2023 was 80 basis points of potential sales, driven by rationalization post-GSK and reduced spend in the US respiratory market [1][2] Question: Volume performance in EMEA and LatAm - Volume declines in EMEA and LatAm were noted, particularly in Latin America, linked to hyperinflation in Argentina [128][123] Question: Respiratory health performance in Q4 - Respiratory health saw strong growth in Q4, driven by geographic diversity and product portfolio strength, with no significant one-offs or inventory discrepancies [64][65] Question: Innovation and R&D spend - R&D spend as a percentage of sales declined due to efficiencies and accounting changes, but the company remains committed to innovation, with 67 new product launches in 2023 [7][121] Question: Share buyback and capital allocation - The company plans a £500 million share buyback in 2024, with flexibility to execute it through open market purchases or placings with GSK and Pfizer [86][145] Question: Pricing and volume growth in 2024 - The company expects pricing to contribute more to growth than volume in 2024, with a long-term goal of a 50-50 split between the two [50][137]

2023 Full year results February 2024 These forward-looking statements and views may be based on a number of assumptions and, by their nature, involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future and/or are beyond Haleon's control or precise estimate. Such risks, uncertainties and other factors that could cause Haleon's actual results, performance or achievements to differ materially from those in th ...

Adjusting Items include the following: • Transaction related costs: Transaction related accounting or other adjustments related to significant acquisitions including deal costs and other pre-acquisition costs when there is certainty that an acquisition will complete. It also includes costs of registering and issuing debt and equity securities and the effect of inventory revaluations on acquisitions. Free cash flow Free cash flow is calculated as net cash inflow from operating activities plus cash inflows fr ...

Then Caltrate was also more of a one-time thing, the distributor change in China and then last year Southeast Asia was very strong. So, again, I think not concerned about Caltrate, particularly not for China where the biggest market is. And moreover with VMS I think we remain confident in the category, and it is back to growth now, so we had two strong years of growth in VMS. And I think now it is coming back with Emergen-C down, but Centrum more than making up for that. Thank you very much. Operator Can yo ...

2023 Half year results August 2023 This presentation contains certain statements that are, or may be deemed to be, "forward-looking statements" (including for purposes of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements give Haleon's current expectations and projections about future events, including strategic initiatives and future financial condition and perfo ...

Sonya Ghobrial - Head, Investor Relations Brian McNamara - Chief Executive Officer Tobias Hestler - Chief Financial Officer Haleon plc (NYSE:HLN) Q2 2023 Earnings Conference Call August 2, 2023 5:00 AM ET Conference Call Participants Sonya Ghobrial Just to remind listeners on the call that in the discussions today, the company may make certain forward-looking statements including those that refer to our estimates, plans and expectations. Please refer to this morning's announcement and the company's UK and S ...

Exhibit 99.1 2 August 2023 2023 Half year results Six months ended 30 June 2023 (unaudited) Strong growth, driven by price with another quarter of positive volume mix Increased operating profit given positive operational leverage Strong execution in delivering on deleveraging commitment Well placed for future growth, updated guidance | Reported results | | | Adjusted results | 1 | | | --- | --- | --- | --- | --- | --- | | Six months ended 30 June | 2023 | vs 2022 | | 2023 | vs 2022 | | Revenue | £5,738m | 1 ...